1.The significance of Treg and T lymphocyte subsets in acute myelocytic leukemia
Lingjun KONG ; Jian GE ; Ruixiang XIA
Acta Universitatis Medicinalis Anhui 2015;(4):512-514,515
Objective To explore the alterations, relationship and clinical significance of CD4 +CD25 +CD127 low/ -
regulatory T cells ( Treg ) and lymphocyte subsets in peripheral blood of patients with acute myelocytic leukemia ( AML) . Methods The level of peripheral blood lymphocyte subsets and Treg of untreated AML patients and com-plete remission( CR) patients were tested by flow cytometry,and were compared with that of 30 normal controls. Re-sults The proportions of Treg were much higher in untreated AML patients and CR patients than in normal con-trols, while the mean proportion of Treg in untreated AML patients was higher than that in CR patients(P<0. 05). The proportions of NK( CD3 -CD16 +CD56 +) cells in untreated AML patients and CR patients were both decreased compared with normal controls,and the mean proportion of NK cells in untreated AML patients was lower than that in CR patients(P<0. 05). Compared with the normal controls,the proportions of CD3 +T cell, CD4 +T cell,and the ratio of CD4 +/CD8 + decreased in untreated AML patients ( P <0. 05 ) , but the proportions of CD8 +T cell was higher than in normal controls;the proportions of CD3 +T cell, CD4 + T cell, CD8 +T cell and the ratio of CD4 +/CD8 + in CR patients were close to the proportions in normal controls, but there was significant difference between CR patients and untreated AML patients(P<0. 05). Conclusion The increase of Treg, CD8 +T cell and decrease of NK cells, CD3 +T cell, CD4 +T cell, and the ratio of CD4 +/CD8 + in peripheral blood of patients with AML in-dicate that the immune function of patients with AML is depressed. Treg control the immune response of CD8 +T cells,at the same time inhibit the natural immune response of NK cells, playing a major role in the disorders of CD4 +T cells and CD8 +T cell balance,and closely relate with the development of AML. The immune treatment of patients with AML will be optimised by reducing the amount of Treg or removing the suppression function.
2.Expression and significance of 12-lipoxygenase in human glioma
Ruixiang GE ; Lili SHENG ; Shanshui XU ; Yinhua LIU ; Guoxiang XU ; Sansong CHEN ; Jie MAO
Chinese Journal of Clinical Oncology 2015;42(19):953-956
Objective:To investigate the expression and clinical significance of 12-lipoxygenase (12-LOX) in glioma. Methods:12-LOX expression in 40 glioma cases and 10 normal human-brain tissues was assayed by immunohistochemistry. Clinicopathological data were analyzed to reveal the association between 12-LOX expression and prognosis of glioma patients. Results:12-LOX was weak-ly expressed in the normal human brain tissues, whereas 12-LOX was strongly expressed (72.5%) in glioma tissues (P<0.05). The strong 12-LOX expression was correlated with the histopathological grading of glioma (P=0.012), whereas 12-LOX expression was not correlated with factors such as patient gender and age, tumor size, and Karnofsky Performance Score. Median survival time was longer in the group with low 12-LOX expression (25.6 months) than in the group with high 12-LOX expression (13.2 months) (P<0.05). Con-clusion:Abnormal 12-LOX expression is implicated in glioma. 12-LOX expression was correlated with the histopathological grading of glioma and was closely associated with patient prognosis.
3.The Role of Signaling Pathways in Invasion and Migration of Glioma
Journal of Shenyang Medical College 2016;18(4):298-301
Glioma is the most commonly diagnosed central nervous system tumors.The standard treatment for glioma is combina-tion of surgery,radiotherapy and chemotherapy.The main cause of the treatment failure is the highly invasive and diffusely infiltrative nature of glioma.With the development of genetics and molecular biology, signaling mechanisms that drive glioma invasiveness has been recognized.Various signaling pathways are involved in development of glioma,and have emerged as promising therapeutic targets.
4.Resistance to daunorubicin in acute myeloid leukemia is associated with mutations in the TET2 gene
Liu YANG ; Jian GE ; Ruixiang XIA
Acta Universitatis Medicinalis Anhui 2018;53(2):246-250
Objective To investigate the effect of leukemia-related genes on drug resistance in patients with acute myeloid leukemia (AML). Methods 74 patients with newly diagnosed AML were selected and 54 leukemia-associated genes of all patients were sequenced by second-generation gene sequencing. The gene with the highest mutation rate was further analyzed in association with resistance to several common chemotherapy medicines in in vitro drug sensitivity assays. In addition, in vitro drug resistance data were compared with the clinical data of patients. Results The TET2 gene was the most frequent mutation among 74 patients with newly diagnosed AML, with 11 positive patients. Among these 11 TET2 positive patients, 9 (81. 82% ) were resistant to daunorubicin, while only 4 (6. 35% ) out of 63 TET2 negative patients were resistant to daunorubicin. Besides, there was no significant difference between in vitro resistance rate to daunorubicin and the clinical data of patients. Conclusion TET2 gene mutation is associated with resistance to daunorubicin in AML patients, which may become an important indicator of the therapeutic efficacy of DA regimen.
5.Research Progress of the Relationship between miRNA-204 and Cancers
Haibo JIANG ; Ruixiang GE ; Dongxi QIAN ; Jie MAO
Journal of Shenyang Medical College 2016;18(6):479-482
miRNA-204 is widely expressed in human body and also aberrantly expressed in almost all human cancers. It is proved that miRNA-204 plays an important role in the occurrence and development of cancers through regulating its target genes in human body. miRNA-204 is often used as a tumor suppressor to inhibit tumor invasion and metastasis through the related molecular mechanism. Meanwhile,miRNA-204 can also be used as potential molecular marker in the treatment of cancers. With a deeper study of miRNA-204,it is possible to provide new ideas for the prevention and treatment of cancers.
6.Study on the relationship of platelet specific-autoantibodies with therapeutic outcomes by dexamethasone in immune thrombocytopenia purpura.
Yang CHEN ; Jian GE ; Min RUAN ; Lingyan ZHU ; Yanyan XIE ; Ruixiang XIA ; Heyu NI ; Qingshu ZENG
Chinese Journal of Hematology 2015;36(3):202-205
OBJECTIVETo investigate the different outcomes by dexamethasone in adults immune thrombocytopenia purpura (ITP) with different types of platelet specific-autoantibodies.
METHODSA total of 185 ITP were enrolled, 61 males and 124 females, with a median age of 42 (18-83) years, including 117 newly diagnosed, 35 persistent, and 33 chronic cases. All the patients received the dexamethasone at an initial dose of 40 mg per day for 4 days and a low dose of 5-10 mg for 3-4 weeks. The platelet specific-autoantibodies were identified by the modified monoclonal antibody-specific immobilization of platelet antigen (MAIPA) assay.
RESULTSAmong the IgG positive patients, the response rates in anti-GPIIb/IIIa antibody, anti-GPIbα antibody, both antibody positive, and both antibody negative were 87.5%, 50.0%, 68.0%, and 72.3% (χ²=11.489, P<0.05), respectively. Among the IgM positive patients, the response rates in the four groups were 82.1%, 71.4%, 61.9%, and 68.9% (χ²=2.719, P=0.437), respectively. Among the GPIbα antibody positive patients, the response rates in IgG alone, IgM alone, both positive, and both negative were 52.4%, 59.1%, 76.1%, and 77.9% (χ²=10.811, P<0.05), respectively. Among the GPIIb/IIIa antibody positive patients, the response rates in the four groups were 73.3%, 71.0%, 78.6%, and 66.3% (χ²=1.374, P=0.719), respectively.
CONCLUSIONITP patients with GPIbα-IgG antibody have worse response to dexamethasone treatment.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal ; Autoantibodies ; Blood Platelets ; Dexamethasone ; Female ; Humans ; Male ; Middle Aged ; Platelet Glycoprotein GPIIb-IIIa Complex ; Purpura, Thrombocytopenic, Idiopathic ; Young Adult